Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends ...

In the primary analysis for Harmoni-2, ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS), achieving a hazard ...

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS) by independent radiologic review committee (IRRC), ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.